| State of the art treatment of chronic lymphocytic leukaemia. | |
| | |
MedLine Citation:
|
PMID: 21095047 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The management of chronic lymphocytic leukaemia is currently undergoing profound changes. Several drugs like bendamustine, alemtuzumab and rituximab have recently been approved for CLL treatment by regulatory agencies. New and very promising compounds like lenalidomide, ofatumumab, GA101, flavopiridol, or ABT-263 are currently investigated in clinical trials and are likely to further enlarge the therapeutic armamentarium in the next years. Latest results show that chemoimmunotherapies like FCR (fludarabine, cyclophosphamide and rituximab) may improve the life expectancy of CLL patients. This new paradigm will modify the way of CLL management in a radical manner. Finally, the development of new biological markers that describe distinct forms of CLL allows to enter the era of personalized therapy similar to other malignancies. |
| | |
Authors:
|
Michael Hallek; Natali Pflug |
Related Documents
:
|
16296927 - Patterns of use of nonbiomedical medicine services by nonbiomedical medicine providers. 15016787 - A postal survey of hydrosalpinx management prior to ivf in the united kingdom. 16215057 - Management of the home parenteral nutrition patient. 15025007 - Migraine mechanism and management. 3478397 - A high-copper amalgam evaluated after three years in city and country practices. 7091177 - Persistent hypertension after resection of a pheochromocytoma. |
Publication Detail:
|
Type: Journal Article Date: 2010-11-20 |
Journal Detail:
|
Title: Blood reviews Volume: 25 ISSN: 1532-1681 ISO Abbreviation: Blood Rev. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8708558 Medline TA: Blood Rev Country: England |
Other Details:
|
Languages: eng Pagination: 1-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010. Published by Elsevier Ltd. |
Affiliation:
|
Klinik I für Innere Medizin, German CLL Study Group, University of Cologne, Kerpener Strasse 62, 50937 Köln, Germany. Michael.hallek@uni-koeln.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Teachers' experiences of English-language-taught degree programs within health care sector of Finnis...
Next Document: JAK2 inhibitors: What's the true therapeutic potential?